February 6, 2026
Attomarker launches Acceleration Round to further progress commercial, regulatory and business development milestones
Attomarker has today commenced a funding acceleration round to support commercial rollout, regulatory progress, further clinical validation, and extension of its immune profiling portfolio.
Attomarker Ltd, a UK-based diagnostics company, has announced the launch of an Acceleration Round as it enters the next phase of its commercial and clinical development.
Attomarker develops multiplex immune diagnostics that deliver clinically relevant immune profiling from a single, small blood sample within minutes. The company’s tests are designed for use in real clinical settings and are already being used by clinicians.
Attomarker’s current focus is on immune profiling in patients suffering with Long Covid, estimated to be more than 65 million people worldwide. The Attomarker Covid Antibody Spectrum Test allows immune classification of patients into one of three distinct endotypes, supporting identification of appropriate treatment options, as well as monitoring disease recovery. The company has two other Long Covid companion tests in its development pipeline.
Attomarker recently signed a strategic co-development agreement with EpitogenX, to leverage their next generation antigen technology with Attomarker’s technology and diagnostics expertise to bring immune profiling to other immune conditions currently underserved with diagnostic options. Early targets including Lyme disease, a $10 billion testing market, and Hashimoto’s disease, an autoimmune disorder thought to affect between 5 and 10% of the global population.
The company is supported by a strong intellectual property position, holding eight granted patents with a further patent pending, covering underlying diagnostics technology and system architecture with a later focus on specific disease indications too.
Attomarker’s diagnostics operate on a CE-marked benchtop device that is already approved and in clinical use. A handheld device is currently in development as an additional deployment option, opening up the growing market of consumer-led diagnostics.
The Acceleration Round supports commercial rollout, regulatory progress, further clinical validation, and extension of Attomarker’s immune profiling portfolio within Long Covid.
The funding round is being hosted on CrowdCube, the UK’s regulated equity crowdfunding platform.
Retail investor information is available via Crowdcube:
Information for non-retail investors is available here:
Notes to editors
This announcement is provided for information purposes only and does not constitute investment advice or an invitation to invest.
About Attomarker
Attomarker Ltd is a UK-based diagnostics company developing multiplex immune profiling technologies designed to support clinical decision-making in complex disease settings. The company’s diagnostics technology enables rapid, clinically relevant analysis from a single small blood sample, supporting real-world clinical use.
Attomarker is a multi-award-winning spin-out from the research group of Professor Andrew Shaw at University of Exeter. The company won the OBN Life Sciences “One to Watch” award, was selected as a candidate for the £10 million Longitude Prize in the fight against antimicrobial resistance and was featured by the Science Museum’s international “Superbugs: The End of Antibiotics” exhibition highlighting approaches to antimicrobial resistance.
Attomarker holds a strong intellectual property position protecting its core diagnostics technology and system architecture, and its tests are already in clinical use.
For media enquiries:
Andrew Vincent
Chief Marketing Officer
andrew.vincent@attomarker.com